抄録
Since July 1994, MCN has been used for patients with hepatocellular carcinoma (HCC) in our institute. All our new patients were classified by a new prognostic staging system, modified JIS score, combined liver damage grades (A, B, and C) and TNM staging by the Liver Cancer Study Group of Japan criteria (stage 0-IV).
In the m-JIS score 1 group, cumulative 1-, 3-, and 5-year survival rates in MCN group were 98.3, 87.6, 73.3%, and in hepatic resection (Hr) group were 100, 86.8, 65.1% (p = 0.8550). In the m-JIS score 2 group, cumulative 1-, 3-, and 5-year survival rates in MCN group were 98.9, 86.4, 76.2%, and in Hr group were 79.7, 58.9, 58.9% (p = 0.0001). In the m-JIS score 3 group, cumulative 1-, 3-, and 5-year survival rates in MCN group were 94.3, 61.4, 36.0%, and in Hr group were 88.9, 71.1, - % (p = 0.9393).
In each m-JIS score group, cumulative 1-, 3-, and 5-year survival rates in MCN group and in Hr group were compared. And no difference of survival rates between MCN group and Hr group in each m-JIS score groups was noted.
In conclusion, MCN can be a first choice for the treatment of HCC.
